Effects of vesnarinone on peripheral circulating levels of cytokines and cytokine receptors in patients with heart failure: A report from the Vesnarinone Trial

Chest

Volumn 120, Issue 2, 2001, Pages 453-459

  Deswal, Anita ^a   Petersen, Nancy J ^a   Feldman, Arthur M ^b   White, Bill G ^c   Mann, Douglas L ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

^c Clinical Cardiovascular Research   (United States)

Author keywords

Cytokine; Heart failure; Interleukin 6; Receptor; Soluble interleukin 6 receptor; Soluble tumor necrosis factor receptor type 1; Soluble tumor necrosis factor receptor type 2; Tumor necrosis factor ; Vesnarinone

Indexed keywords

CYTOKINE; CYTOKINE RECEPTOR; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; PIPERANOMETOZINE; PLACEBO; RECEPTOR SUBTYPE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE COURSE; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFECT; DRUG POTENCY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEART FAILURE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL;

EID: 0034827651     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.120.2.453     Document Type: Article

References (28)

1. Is tumor necrosis factor an important neurohormonal mechanism in chronic heart failure?
2. Basic mechanisms in heart failure: The cytokine hypothesis
3. Membrane current changes responsible for the positive inotropic effect of OPC-8212, a new positive inotropic agent, in single ventricular cells of the guinea pig heart
4. Cyclic AMP-dependent and cyclic AMP-independent actions of a novel cardiotonic agent, OPC-8212
5. Effects of new inotropic agents on cyclic nucleotide metabolism and calcium transients in canine ventricular muscle
6. Evaluation of a new inotropic agent, OPC-8212, in patients with dilated cardiomyopathy and heart failure
7. Sustained inotropic effects of a new cardiotonic agent. OPC-8212 in patients with chronic heart failure
8. A placebo-controlled, randomized, double-blind study of OPC-8212 in patients with mild chronic heart failure
9. Effects of vesnarinone on morbidity and mortality in patients with heart failure
10. Inhibition of cytokine production by a new inotropic agent, vesnarinone, in human lymphocytes, t cell line, and monocytic cell line
11. Differential modulation of cytokine production by drugs: Implications for therapy in heart failure
12. The effect of vesnarinone on TNF production in human peripheral blood mononuclear cells and microglia: A preclinical study for the treatment of multiple sclerosis
13. Vesnarinone, a new inotropic agent, inhibits cytokine production by stimulated human blood from patients with heart failure
14. The search for the ideal positive inotropic agent
15. A dose-dependent increase in mortality with vesnarinone among patients with severe heart failure: Vesnarinone Trial Investigators
16. R&D Systems Cytokine Bulletin
17. Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction: A report from the studies of left ventricular dysfunction (SOLVD)
18. Tumor necrosis factor-α and tumor necrosis factor receptors in the failing human heart
19. Influence of collection and separation of blood samples on plasma IL-1, IL-6 and TNF-α concentrations
20. Measuring cytokine levels in blood: Importance of anticoagulants, processing, and storage conditions
21. Incidence and specificity of interference in two-site immunoassays
22. Randomized investigation of effects of pentoxifylline on left ventricular performance in idiopathic dilated cardiomyopathy
23. Vesnarinone and amrinone reduce the systemic inflammatory response syndrome
24. Amiodarone inhibits production of tumor necrosis factor-α by human mononuclear cells: A possible mechanism for its effect in heart failure
25. Effects of amiodarone on tumor necrosis factor-α levels in congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy
26. Interleukin-6 correlates with hemodynamic impairment during dobutamine administration in chronic heart failure
27. Influence of pentoxifylline on cytokine levels and inflammatory parameters in septic shock
28. A phase I trial of tumor necrosis factor receptor (p75) fusion protein (TNFR:Fc) in patients with advanced heart failure